Literature DB >> 27239126

Construction of retroviral vectors to induce a strong expression of human class interferon gene in human hepatocellular carcinoma cells in vitro.

G W Cao1, P Du1, Z T Qi1, X T Kong1.   

Abstract

AIM: To establish the hepatoma cell-specific expression of human interferon (IFN) gene mediated by retroviral vectors
METHODS: Human interferon α and interferon β complementary DNA (IFN cDNA) were cloned into the polylinker site of pMNSM retroviral vector to construct recombinant retroviral vectors pMNSIFNA and pMNSIFNB, with the transcription of IFN gene being driven by Simian virus 40 early region promoter (SV40) early region promoter. IFN cDNAs were also cloned into pMNAIFNA, pAMNSIFNA, and pMNAIFNB, with the transcription of IFN gene being driven by SV40 early region promoter regulated by α-fetoprotein enhancer. Next, the retroviral constructs were introduced into retroviral amphotropic packaging cells using the lipofectamine-mediated gene transfer procedure. The rate of plasmid transfection was (4-40) × 10(3) colonies/μg DNA/10(6) PA317 cells. The rate of retrovirus infection was (5-500) × 10(4) colony forming units (CFU)/mL. Further, the recombinant retroviruses were used to infect human hepatoma cells, renal carcinoma cells, and melanoma cell lines in the presence of 4 μmg/L polybrene.
RESULTS: Northern and Dot hybridization of total RNA from the neomycin-resistant colonies and IFN expression assay indicated that human α fetoprotein enhancer induced efficient and specific transcription and expression of IFN genes driven by the promoter of different origins in human hepatoma cells, leading to high production of α fetoprotein.
CONCLUSION: Cis active element of α-fetoprotein gene can drive specific expression of IFN genes in human hepatoma cells, which provides some valuable data for the hepatoma-specific immune gene therapy.

Entities:  

Keywords:  Carcinoma, hepatocellular; Gene expression; Gene therapy; Genes, regulatory; Interferon alpha; Interferon beta; Liver neoplasms; Retroviridae

Year:  1997        PMID: 27239126      PMCID: PMC4842867          DOI: 10.3748/wjg.v3.i3.139

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  7 in total

1.  [Basic research for interferon gene therapy against malignant glioma].

Authors:  M Mizuno; J Yoshida; K Sugita; Y Hayashi; K Yagi
Journal:  No Shinkei Geka       Date:  1992-05

2.  Use of retroviral vectors for gene transfer and expression.

Authors:  A D Miller; D G Miller; J V Garcia; C M Lynch
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

Review 3.  Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

Authors:  M P Colombo; G Forni
Journal:  Immunol Today       Date:  1994-02

4.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro.

Authors:  T Tanaka; F Kanai; S Okabe; Y Yoshida; H Wakimoto; H Hamada; Y Shiratori; K Lan; M Ishitobi; M Omata
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

5.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.

Authors:  R G Vile; I R Hart
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

6.  Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy.

Authors:  B E Huber; C A Richards; T A Krenitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

7.  Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans.

Authors:  P Hwu; J Yannelli; M Kriegler; W F Anderson; C Perez; Y Chiang; S Schwarz; R Cowherd; C Delgado; J Mulé
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

  7 in total
  1 in total

1.  TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer.

Authors:  Shan-Yu Guo; Qin-Long Gu; Zheng-Gang Zhu; He-Qun Hong; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.